TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$112 Million

Stoke Therapeutics, Inc.

Follow-on Offering

Bookrunner, November 2020

Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. is a biopharmaceutical company focused on pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression. The Company develops novel antisense oligonucleotide (ASO) therapies that target ribonucleic acid (RNA) and modulate precursor-messenger RNA (pre-mRNA) splicing to reduce non-productive mRNA and increase productive mRNA. The Company’s ASOs utilize its proprietary technology platform, Targeted Augmentation of Nuclear Gene Output (TANGO), and are designed to increase the expression of proteins by individual genes. The Company’s lead product candidate, STK-001, is designed to treat Dravet syndrome, which is a severe and progressive genetic epilepsy.